The Ban Was Supposed To Be The Easy Part
The Federal Trade Commission and seven states filed a motion asking a federal judge to hold Martin Shkreli in civil contempt. The filing alleges that Shkreli repeatedly violated a 2022 court order that permanently barred him from participating in the pharmaceutical industry.
According to the FTC, Shkreli publicly traded pharmaceutical-industry stocks in at least 60 companies and used livestreams and social-media posts to discuss, influence and speculate about pharmaceutical businesses. The allegations are just that—allegations in a contempt filing—but they are also impressively direct for a court order that used the word “lifetime.”
Daraprim, But Make It A Recurring Series
The 2022 order followed a ruling that Shkreli organized an anticompetitive scheme involving Daraprim, a drug used to treat a rare and potentially fatal infection. The FTC says the court found that the scheme helped protect Shkreli’s ability to raise the price from $17.50 per tablet to $750.
That history makes the alleged return to biotech commentary feel less like a career pivot and more like a man walking back into the same courtroom wearing a different hat. The court also ordered him to disgorge more than $64 million and banned him from the industry.
He Apparently Had A Channel
The FTC says Shkreli publicized the alleged violations through YouTube, X and Reddit, including livestreams about trading biotech stocks. Prosecutors and regulators generally prefer defendants to be discreet. Shkreli, according to the filing, chose the content-creator route.
The agency is asking the court to require him to divest pharmaceutical stocks, pay profits from the trades with interest, and face escalating consequences for future violations, including possible incarceration. The court has not yet ruled on the motion.
The Bottom Line
A lifetime ban is not normally a networking suggestion. The case will turn on what the injunction covers and what Shkreli actually did, but the FTC’s allegation is a spectacularly simple one: the man who was told to leave the pharmaceutical industry may have kept participating in it, publicly, with an audience.
Source
Federal Trade Commission: FTC and states ask court to hold Martin Shkreli in contempt